Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 19, 2021 in Diabetes mellitus | 0 comments

In a nutshell

This study evaluated the safety of anti-diabetic drugs in the risk of fractures based on available data from clinical trials. The data showed differences in associations between the use of anti-diabetic drugs and fracture risk.

Some background

Patients with type 2 diabetes (T2D) are more prone to bone fragility (increased bone fracture risk). This is possibly related to a deteriorated bone tissue or decreases in bone mineral levels in tissues (bone mineral density; BMD).

Bone fractures can have serious consequences for patients with T2D. Currently, it remains unclear whether anti-diabetic drug therapies may also affect bone quality in patients with T2D. There is a need to investigate the association between fracture risk and anti-diabetic drug use.   

Methods & findings

This review included 117 studies with 221,364 patients that had T2D. A wide range of anti-diabetic drugs was used among studies. Fracture effects of anti-diabetic drug use were recorded. 

All fractures were graded as high or moderate quality in this review. Trelagliptin (Zafatek), a DPP-4 inhibitor, was associated with a significantly higher (by 3.51 times) risk of fractures compared to placebo. Other DPP-4 inhibitors such as omarigliptin (Marizev), sitagliptin (Januvia), vildagliptin (Galvus), and saxagliptin (Onglyza) were also associated with a higher risk of fractures compared to placebo.

Albiglutide (Tanzeum), a GLP-1 receptor agonist was associated with a 71% lower risk of fractures compared to placebo. Other GLP-1 receptor agonists such as dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Saxenda), semaglutide (Ozempic), and lixisenatide (Lyxumia) were associated with slightly lower risks of fractures compared to placebo.

Voglibose (Voglib), an α-glucosidase inhibitor, significantly decreased the risk of fracture compared to placebo by 97%. Other anti-diabetic drugs may increase or decrease the risk of fractures, however, no significant differences were found.

The bottom line

The study indicated that some anti-diabetic drugs can influence the risk of fractures. The authors suggest that there is a need to weigh drug effectiveness with treatment benefits and risks for patients.

The fine print

Limited data were available for some anti-diabetic drugs in a few studies, so their effects could not be evaluated. In some cases, combining data for fracture effects was not possible due to limited data.

Published By :

Frontiers in Endocrinology

Date :

Nov 02, 2021

Original Title :

Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.

click here to get personalized updates